Sign in to view content

Clinical Evaluation and PK/PD Modeling of the DARPin Therapeutic Abicipar for the Treatment of Neovascular Age‐Related Macular Degeneration

Peter K. Kaiser, MD FASRS

Video
Published 2020

Related

Abicipar Phase 2 MAPLE Trial: Evaluation of All Patients With Post-Injection Inflammation
Tarek S. Hassan, MD, FASRS
Annual Meeting Talks
2020
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial
John W. Kitchens, MD
Annual Meeting Talks
2021
Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2020

Category: Pharmacology

See more